186 related articles for article (PubMed ID: 26614576)
1. Human papillomavirus and induction chemotherapy versus concurrent chemoradiotherapy in locally advanced oropharyngeal cancer: The Dana Farber Experience.
Lorch JH; Hanna GJ; Posner MR; O'Neill A; Thotakura VL; Limaye SA; Rabinowits G; Sher DJ; Tishler RB; Haddad RI
Head Neck; 2016 Apr; 38 Suppl 1():E1618-24. PubMed ID: 26614576
[TBL] [Abstract][Full Text] [Related]
2. Comparative effectiveness of induction chemotherapy for oropharyngeal squamous cell carcinoma: A population-based analysis.
Sher DJ; Schwartz DL; Nedzi L; Khan S; Hughes R; Fidler MJ; Koshy M
Oral Oncol; 2016 Mar; 54():58-67. PubMed ID: 26794877
[TBL] [Abstract][Full Text] [Related]
3. Impact of cisplatin dose intensity on human papillomavirus-related and -unrelated locally advanced head and neck squamous cell carcinoma.
Spreafico A; Huang SH; Xu W; Granata R; Liu CS; Waldron JN; Chen E; Ringash J; Bayley A; Chan KK; Hope AJ; Cho J; Razak AA; Hansen A; Jang R; Perez-Ordonez B; Weinreb I; Bossi P; Orlandi E; Licitra LF; Song Y; O'Sullivan B; Siu LL; Kim J
Eur J Cancer; 2016 Nov; 67():174-182. PubMed ID: 27669504
[TBL] [Abstract][Full Text] [Related]
4. Induction chemotherapy followed by concurrent chemoradiotherapy for advanced stage oropharyngeal squamous cell carcinoma with HPV and P16 testing.
Flavill E; Fang YV; Miles B; Truelson J; Perkins S
Ann Otol Rhinol Laryngol; 2014 May; 123(5):365-73. PubMed ID: 24687594
[TBL] [Abstract][Full Text] [Related]
5. Patterns of Care and Comparative Effectiveness of Intensified Adjuvant Therapy for Resected Oropharyngeal Squamous Cell Carcinoma in the Human Papillomavirus Era.
Sher DJ; Nedzi L; Khan S; Hughes R; Sumer BD; Myers LL; Truelson JM; Koshy M
JAMA Otolaryngol Head Neck Surg; 2016 Aug; 142(8):777-88. PubMed ID: 27368076
[TBL] [Abstract][Full Text] [Related]
6. Standard of care vs reduced-dose chemoradiation after induction chemotherapy in HPV+ oropharyngeal carcinoma patients: The Quarterback trial.
Misiukiewicz K; Gupta V; Miles BA; Bakst R; Genden E; Selkridge I; Surgeon JT; Rainey H; Camille N; Roy E; Zhang D; Ye F; Jia R; Moshier E; Bonomi M; Hwang M; Som P; Posner MR
Oral Oncol; 2019 Aug; 95():170-177. PubMed ID: 31345387
[TBL] [Abstract][Full Text] [Related]
7. Impact of human papillomavirus on outcome in patients with oropharyngeal cancer treated with primary surgery.
Broglie MA; Stoeckli SJ; Sauter R; Pasche P; Reinhard A; de Leval L; Huber GF; Pezier TF; Soltermann A; Giger R; Arnold A; Dettmer M; Arnoux A; Müller M; Spreitzer S; Lang F; Lutchmaya M; Stauffer E; Espeli V; Martucci F; Bongiovanni M; Foerbs D; Jochum W
Head Neck; 2017 Oct; 39(10):2004-2015. PubMed ID: 28691255
[TBL] [Abstract][Full Text] [Related]
8. T-category remains an important prognostic factor for oropharyngeal carcinoma in the era of human papillomavirus.
Mackenzie P; Pryor D; Burmeister E; Foote M; Panizza B; Burmeister B; Porceddu S
Clin Oncol (R Coll Radiol); 2014 Oct; 26(10):643-7. PubMed ID: 25001635
[TBL] [Abstract][Full Text] [Related]
9. Racial survival disparity in head and neck cancer results from low prevalence of human papillomavirus infection in black oropharyngeal cancer patients.
Settle K; Posner MR; Schumaker LM; Tan M; Suntharalingam M; Goloubeva O; Strome SE; Haddad RI; Patel SS; Cambell EV; Sarlis N; Lorch J; Cullen KJ
Cancer Prev Res (Phila); 2009 Sep; 2(9):776-81. PubMed ID: 19641042
[TBL] [Abstract][Full Text] [Related]
10. Prognostic impact of human papillomavirus status, survivin, and epidermal growth factor receptor expression on survival in patients treated with radiochemotherapy for very advanced nonresectable oropharyngeal cancer.
Semrau R; Duerbaum H; Temming S; Huebbers C; Stenner M; Drebber U; Klussmann JP; Müller RP; Preuss SF
Head Neck; 2013 Sep; 35(9):1339-44. PubMed ID: 23042483
[TBL] [Abstract][Full Text] [Related]
11. It is not just IMRT: Human papillomavirus related oropharynx squamous cell carcinoma is associated with better swallowing outcomes after definitive chemoradiotherapy.
Naik M; Ward MC; Bledsoe TJ; Kumar AM; Rybicki LA; Saxton JP; Burkey BB; Greskovich JF; Adelstein DJ; Koyfman SA
Oral Oncol; 2015 Aug; 51(8):800-4. PubMed ID: 25977228
[TBL] [Abstract][Full Text] [Related]
12. Induction chemotherapy followed by concurrent chemoradiation versus concurrent chemoradiation alone in the definitive management of p16-positive oropharyngeal squamous cell carcinoma with low-neck or N3 disease.
Bhattasali O; Han J; Thompson LDR; Buchschacher GL; Abdalla IA; Iganej S
Oral Oncol; 2018 Mar; 78():151-155. PubMed ID: 29496043
[TBL] [Abstract][Full Text] [Related]
13. Human papillomavirus DNA detection in fine-needle aspirates as indicator of human papillomavirus-positive oropharyngeal squamous cell carcinoma: A prospective study.
Sivars L; Landin D; Haeggblom L; Tertipis N; Grün N; Bersani C; Marklund L; Ghaderi M; Näsman A; Ramqvist T; Nordfors C; Munck-Wikland E; Tani E; Dalianis T
Head Neck; 2017 Mar; 39(3):419-426. PubMed ID: 27898186
[TBL] [Abstract][Full Text] [Related]
14. Clinical characteristics of Japanese oropharyngeal squamous cell carcinoma positive for human papillomavirus infection.
Nomura F; Sugimoto T; Kitagaki K; Ito T; Kawachi H; Eishi Y; Watanabe K; Igaue M; Shimizu N; Tomita M; Kitamura K; Kishimoto S
Acta Otolaryngol; 2014 Dec; 134(12):1265-74. PubMed ID: 25399886
[TBL] [Abstract][Full Text] [Related]
15. Effect of human papillomavirus on patterns of distant metastatic failure in oropharyngeal squamous cell carcinoma treated with chemoradiotherapy.
Trosman SJ; Koyfman SA; Ward MC; Al-Khudari S; Nwizu T; Greskovich JF; Lamarre ED; Scharpf J; Khan MJ; Lorenz RR; Adelstein DJ; Burkey BB
JAMA Otolaryngol Head Neck Surg; 2015 May; 141(5):457-62. PubMed ID: 25742025
[TBL] [Abstract][Full Text] [Related]
16. Impact of cisplatin dose and smoking pack-years in human papillomavirus-positive oropharyngeal squamous cell carcinoma treated with chemoradiotherapy.
Oliva M; Huang SH; Xu W; Su J; Hansen AR; Bratman SV; Ringash J; Jang R; Cho J; Bayley A; Hope AJ; Chen E; Giuliani M; Waldron J; Weinreb I; Perez-Ordonez B; Chepeha D; Kim J; O Sullivan B; Siu LL; Spreafico A
Eur J Cancer; 2019 Sep; 118():112-120. PubMed ID: 31330486
[TBL] [Abstract][Full Text] [Related]
17. Toxicity and efficacy of accelerated radiotherapy with concurrent weekly cisplatin for locally advanced head and neck carcinoma.
Driessen CM; Janssens GO; van der Graaf WT; Takes RP; Merkx TA; Melchers WJ; Kaanders HA; van Herpen CM
Head Neck; 2016 Apr; 38 Suppl 1():E559-65. PubMed ID: 25810154
[TBL] [Abstract][Full Text] [Related]
18. Did the addition of concurrent chemotherapy to conventional radiotherapy improve survival for patients with HPV+ve and HPV-ve Oropharynx cancer? A population-based study.
Hall SF; Liu FF; O'Sullivan B; Shi W; Rohland S; Griffiths R; Groome P
Br J Cancer; 2017 Oct; 117(8):1105-1112. PubMed ID: 28829763
[TBL] [Abstract][Full Text] [Related]
19. OPTIMA: a phase II dose and volume de-escalation trial for human papillomavirus-positive oropharyngeal cancer.
Seiwert TY; Foster CC; Blair EA; Karrison TG; Agrawal N; Melotek JM; Portugal L; Brisson RJ; Dekker A; Kochanny S; Gooi Z; Lingen MW; Villaflor VM; Ginat DT; Haraf DJ; Vokes EE
Ann Oncol; 2019 Feb; 30(2):297-302. PubMed ID: 30481287
[TBL] [Abstract][Full Text] [Related]
20. Cystic nodal metastasis in patients with oropharyngeal squamous cell carcinoma receiving chemoradiotherapy: Relationship with human papillomavirus status and failure patterns.
Huang YH; Yeh CH; Cheng NM; Lin CY; Wang HM; Ko SF; Toh CH; Yen TC; Liao CT; Ng SH
PLoS One; 2017; 12(7):e0180779. PubMed ID: 28686646
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
